Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio
Officinae Bio's AI-driven sequence optimization expands Maravai's family of brands, enabling rapid, cost-effective nucleic acid therapy development
SAN DIEGO, February 24, 2025--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio's DNA and RNA business. This acquisition combines Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' leading drug substance manufacturing capabilities, providing customers comprehensive expertise and novel technologies for quick, calculated progression through the mRNA sequence-optimization phase and into clinical testing and commercial manufacturing.
Venice, Italy-based Officinae Bio's proprietary digital platform accelerates the prototyping of mRNA drug candidates, enabling the rapid testing of diverse combinations of capping analogs, chemical modifications, and sequence designs to advance client discovery programs into the clinic.
"We are thrilled to bring Officinae into the Maravai family, where their talented team will add cutting-edge AI-driven sequence design and seamless e-commerce to our TriLink Discovery business. Together, we intend to accelerate the field of next-generation medicines in mRNA and CRISPR, using best-in-class chemistries, processes, and proprietary technologies like CleanCap® analogs," said Trey Martin, CEO of Maravai LifeSciences. "This acquisition also marks our first move into the very important European marketplace with a manufacturing footprint. This market access will fuel our growth across multiple product lines in the post-pandemic era."
Davide De Lucrezia, Chief Executive Officer and co-founder of Officinae Bio commented, "Joining forces with Maravai and TriLink allows us to extend our expertise in AI-driven tools for more customers to accelerate their development and to identify candidate sequences with fewer errors. Along with TriLink's decades of chemical and biological manufacturing experience, we can now supercharge the design-build-test-learn cycle for our customers."
Davide will continue to lead the Officinae Bio team, now a business within Maravai's Nucleic Acid Production segment.
To learn more about Maravai's portfolio and its products and services, visit https://www.maravai.com/.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics and cell and gene therapies companies.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
About Officinae Bio
Officinae Bio is a global leader in the advancement of biologically designed therapeutics through groundbreaking innovations in AI-enabled methodologies for nucleic acid manufacturing. The company is dedicated to pioneering research in gene-modified cell therapy, gene therapy, and RNA therapeutic development with cutting-edge tools and platforms.
DNA Platform
The Vulcanus DNA synthesis platform creates high-precision DNA libraries with exceptional control over variant representation, accelerating lead discovery through targeted sequence exploration with smart mutant libraries.
RNA Platform
The Mercury RNA platform generates libraries of precisely engineered untranslated regions (UTRs), optimizing efficacy and safety through enhanced translational efficiency and tissue-specificity.
Forward-looking Statements
This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to the anticipated benefits of the Officinae Bio acquisition and the expected combined customer offerings, constitute forward-looking statements identified by words like "plan," "expect," "intend," "estimate," "may," "soon," "nears," "slated," "anticipate," or "could" and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, operational risks and competition. These and other risks and uncertainties are described in greater detail in the "Risk Factors" section of our most recent Annual Report on Form 10-K, as well as other reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224396160/en/
Contacts
Media Contact: Liz RobinsonCG Lifetrilink@cglife.com
Investor Contact: Deb HartMaravai LifeSciencesir@maravai.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
28 minutes ago
How major US stock indexes fared Firday, 6/13/2025
Oil prices leaped, and stocks slumped on worries that escalating violence following Israel's attack on Iranian nuclear and military targets could damage the flow of crude around the world, along with the global economy. The S&P 500 sank 1.1% Friday and wiped out what had been a modest gain for the week. The Dow Jones Industrial Average dropped 769 points, and the Nasdaq composite lost 1.3%. Crude prices jumped roughly 7% because Iran is one of the world's major producers of oil and fighting in the region could disrupt the flow. Treasury yields rose with worries about inflation. On Friday: The S&P 500 fell 68.29 points, or 1.1%, to 5,976.97. The Dow Jones Industrial Average fell 769.83 points, or 1.8%, to 42,197.79. The Nasdaq composite fell 255.66 points, or 1.3%, to 19,406.83. The Russell 2000 index of smaller companies fell 39.59 points, or 1.8%, to 2,100.51. For the week: The S&P 500 is down 23.39 points, or 0.4%. The Dow is down 565.08 points, or 1.3%. The Nasdaq is down 123.13 points, or 0.6%. The Russell 2000 is down 31.74 points, or 1.5%. For the year: The S&P 500 is up 95.34 points, or 1.6%. The Dow is down 346.43 points, or 0.8%. The Nasdaq is up 96.03 points, or 0.5%. The Russell 2000 is down 129.65 points, or 5.8%.
Yahoo
28 minutes ago
- Yahoo
Longtime spokesperson Tom Bodett sues Motel 6
The Brief Tom Bodett filed a federal lawsuit against Motel 6, claiming the chain used his voice and name without authorization after their contract ended. The dispute stems from a missed $1.2 million payment and the breakdown of a nearly 40-year partnership between Bodett and the motel brand. Motel 6's parent company, G6 Hospitality, said it was surprised by the lawsuit but expressed appreciation for Bodett's contributions. Tom Bodett, whose warm baritone and iconic line "we'll leave the light on for you" made him the voice of Motel 6 for nearly four decades, is suing the motel chain and its parent company for alleged unauthorized use of his name and voice. According to a lawsuit filed Monday in Manhattan federal court, Bodett said he ended his relationship with Motel 6 after its new owner, India-based travel firm OYO, failed to make a $1.2 million annual payment due on Jan. 7. Their contract was set to expire in November. The backstory Despite the contract lapse, Bodett claims Motel 6 continued using his voice and name on its national reservation phone line. The lawsuit alleges violations of both his contract rights and federal trademark law. Bodett said he attempted to reach a confidential settlement that would honor his legacy and protect Motel 6's reputation and franchisees, but accused the company of responding with "misrepresentations, obfuscations, and delay tactics." The lawsuit seeks $1.2 million in owed compensation, along with additional damages and a share of profits. What they're saying A spokesperson for G6 Hospitality, the parent company of Motel 6, said the company was "surprised" by Bodett's lawsuit but indicated it hoped for an amicable resolution. "We appreciate Mr. Bodett's contributions over the past years," the spokesperson said. "Of course, we will continue to advertise keeping the lights on for you." Bodett, when contacted by email, told Reuters: "The complaint says all there is to say." Tom Bodett became Motel 6's lead spokesman in 1986 and said he coined the phrase "we'll leave the light on for you" during an unscripted ad-lib. His voice became synonymous with the brand's down-to-earth identity and was featured in both radio and TV campaigns for decades. In addition to his advertising work, Bodett is known for his appearances on National Public Radio and for narrating several Ken Burns documentaries. What's next The lawsuit, Bodett et al v G6 Hospitality LLC et al, was filed in the U.S. District Court for the Southern District of New York. It could set a notable precedent for voice usage and contract rights in long-term brand relationships, especially as companies change ownership. The Source This report is based on original reporting from Reuters, which first detailed the lawsuit filed by Tom Bodett against Motel 6 and its parent company G6 Hospitality. The article includes direct quotes from legal filings and statements provided to Reuters by both Bodett and Motel 6.
29 minutes ago
Trump clears path for Nippon investment in US Steel, so long as it fits gov't terms
WASHINGTON -- President Donald Trump on Friday signed an executive order paving the way for a Nippon Steel investment in U.S. Steel, so long as the Japanese company complies with a 'national security agreement' submitted by the federal government. Trump's order didn't detail the terms of the national security agreement. But the iconic American steelmaker and Nippon Steel said in a joint statement that the agreement stipulates that approximately $11 billion in new investments will be made by 2028 and includes giving the U.S. government a ' golden share" — essentially veto power to ensure the country's national security interests are protected against cutbacks in steel production. 'We thank President Trump and his Administration for their bold leadership and strong support for our historic partnership," the two companies said. "This partnership will bring a massive investment that will support our communities and families for generations to come. We look forward to putting our commitments into action to make American steelmaking and manufacturing great again.' The companies have completed a U.S. Department of Justice review and received all necessary regulatory approvals, the statement said. 'The partnership is expected to be finalized promptly,' the statement said. U.S. Steel rose $2.66, or 5%, to $54.85 in afterhours trading Friday. Nippon Steel's original bid to buy the Pittsburgh-based U.S. Steel in late 2023 had been valued at $55 per share. The companies offered few details on how the golden share would work, what other provisions are in the national security agreement and how specifically the $11 billion would be spent. White House spokesman Kush Desai said the order 'ensures U.S. Steel will remain in the great Commonwealth of Pennsylvania, and be safeguarded as a critical element of America's national and economic security.' James Brower, a Morrison Foerster lawyer who represents clients in national security-related matters, said such agreements with the government typically are not disclosed to the public, particularly by the government. They can become public, but it's almost always disclosed by a party in the transaction, such as a company — like U.S. Steel — that is publicly held, Brower said. The mechanics of how a golden share would work will depend on the national security agreement, but in such agreements it isn't unusual to give the government approval rights over specific activities, Brower said. U.S. Steel made no filing with the U.S. Securities and Exchange Commission on Friday. Nippon Steel originally offered nearly $15 billion to purchase U.S. Steel in an acquisition that had been delayed on national security concerns starting during Joe Biden's presidency. As it sought to win over American officials, Nippon Steel gradually increased the amount of money it was pledging to invest into U.S. Steel. American officials now value the transaction at $28 billion, including the purchase bid and a new electric arc furnace — a more modern steel mill that melts down scrap — that they say Nippon Steel will build in the U.S. after 2028. Nippon Steel had pledged to maintain U.S. Steel's headquarters in Pittsburgh, put U.S. Steel under a board with a majority of American citizens and keep plants operating. It also said it would protect the interests of U.S. Steel in trade matters and it wouldn't import steel slabs that would compete with U.S. Steel's blast furnaces in Pennsylvania and Indiana. Trump opposed the purchase while campaigning for the White House, and using his authority Biden blocked the transaction on his way out of the White House. But Trump expressed openness to working out an arrangement once he returned to the White House in January. Trump said Thursday that he would as president have 'total control' of what U.S. Steel did as part of the investment. Trump said then that the deal would preserve '51% ownership by Americans,' although Nippon Steel has never backed off its stated intention of buying and controlling U.S. Steel as a wholly owned subsidiary. 'We have a golden share, which I control,' Trump said. Trump added that he was 'a little concerned' about what presidents other than him would do with their golden share, 'but that gives you total control.' The proposed merger had been under review by the Committee on Foreign Investment in the United States, or CFIUS, during the Trump and Biden administrations. The order signed Friday by Trump said the CFIUS review provided 'credible evidence' that Nippon Steel 'might take action that threatens to impair the national security of the United States,' but such risks might be 'adequately mitigated' by approving the proposed national security agreement. The order doesn't detail the perceived national security risk and only provides a timeline for the national security agreement. The White House declined to provide details on the terms of the agreement. The order said the draft agreement was submitted to U.S. Steel and Nippon Steel on Friday. The two companies must successfully execute the agreement as decided by the Treasury Department and other federal agencies that are part CFIUS by the closing date of the transaction. Trump reserves the authority to issue further actions regarding the investment as part of the order he signed on Friday.
